Efficacy and safety of hematopoietic stem cell remobilization with plerixafor + G-CSF in adult patients with germ cell tumors

Bone Marrow Transplantation

Volumn 47, Issue 10, 2012, Pages 1283-1286

  Horwitz, M E ^a   Long, G ^a   Holman, P ^b   Libby, E ^c   Calandra, G C ^d   Schriber, J R ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d GENZYME CORPORATION   (United States)

^e Banner Blood and Marrow Transplant Program   (United States)

Author keywords

Germ cell tumors; Mobilization; PBSCs; Plerixafor

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ABNORMAL DREAMING; ADULT; APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLURRED VISION; BONE PAIN; CD34 SELECTION; CHILL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENGRAFTMENT; EVENING DOSAGE; FATIGUE; GERM CELL TUMOR; HEMATOPOIETIC STEM CELL; HUMAN; INJECTION SITE REACTION; LIP DISEASE; LIP SWELLING; MALE; NAUSEA; NECK PAIN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; SWELLING; TREATMENT FAILURE;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD34; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84867395614     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.21     Document Type: Article

References (16)

1. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. Highdose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357: 340-348.
2. Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29: 2178-2184.
3. Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235-242.
4. Neben S, Hellman S, Montgomery M, Ferrara J, Mauch P. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol 1993; 21: 156-162.
5. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307-1318.
6. Hatse S, Princen K, Bridger G, De Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002; 527: 255-262.
7. Rosenkilde MM, Gerlach LO, Hatse S, Skerlj RT, Schols D, Bridger GJ et al. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem 2007; 282: 27354-27365.
8. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
9. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
10. Mozobil [package insert]. Cambridge MGC, 2010.
11. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331-338.
12. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J et al. Highdose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 1994; 12: 1223-1231.
13. Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ et al. Doseintensive chemotherapy in refractory germ cell cancer-a phase I/II trial of highdose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932-939.
14. Kobold S, Isernhagen J, Hubel K, Kilic N, Bogner C, Frickhofen N et al. Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients. Bone Marrow Transplant 2011; 46: 1053-1056.
15. Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L, Lanier K et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009; 43: 909-917.
16. Lazarus HM, Stiff PJ, Carreras J, Logan BR, Akard L, Bolwell BJ et al. Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysis. Biol Blood Marrow Transplant 2007; 13: 778-789.